Read by QxMD icon Read

Prostate cancer SNP

Cheng-Hsueh Lee, Jiunn-Bey Pao, Te-Ling Lu, Hong-Zin Lee, Yung-Chin Lee, Chia-Chu Liu, Chao-Yuan Huang, Victor C Lin, Chia-Cheng Yu, Hsin-Ling Yin, Shu-Pin Huang, Bo-Ying Bao
Backgroud: Increasing evidence suggests the involvement of chronic inflammation in the progression of prostate cancer, and prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxygenase-2, catalyzes the rate-limiting steps of the pathway. We hypothesized that genetic variants of PTGS2 can influence the outcome of prostate cancer patients. Methods: We genotyped five haplotype-tagging single-nucleotide polymorphisms (SNPs) to detect common genetic variations across the PTGS2 region in 458 prostate cancer patients treated with radical prostatectomy...
2016: International Journal of Medical Sciences
Reham Helwa, Liv B Gansmo, Pål Romundstad, Kristian Hveem, Lars Vatten, Bríd M Ryan, Curtis C Harris, Per E Lønning, Stian Knappskog
Two functional SNPs (SNP285G > C; rs117039649 and SNP309T > G; rs2279744) have previously been reported to modulate Sp1 transcription factor binding to the promoter of the proto-oncogene MDM2, and to influence cancer risk. Recently, a third SNP (SNP55C > T; rs2870820) was also reported to affect Sp1 binding and MDM2 transcription. In this large population based case-control study, we genotyped MDM2 SNP55 in 10,779 Caucasian individuals, previously genotyped for SNP309 and SNP285, including cases of colon (n = 1,524), lung (n = 1,323), breast (n = 1,709) and prostate cancer (n = 2,488) and 3,735 non-cancer controls, as well as 299 healthy African-Americans...
2016: Scientific Reports
(no author information available yet)
The prostate cancer risk SNP rs7463708 promotes transformation via upregulation of PCAT1 lncRNA.
October 2016: Cancer Discovery
Robert J MacInnis, Daniel F Schmidt, Enes Makalic, Gianluca Severi, Liesel FitzGerald, Matthias Reumann, Miroslav K Kapuscinski, Adam Kowalczyk, Zeyu Zhou, Benjamin W Goudey, Guoqi Qian, Minh Bui, Daniel J Park, Adam Freeman, Melissa C Southey, Ali Amin Al Olama, Zsofia Kote-Jarai, Rosalind A Eeles, John L Hopper, Graham G Giles
BACKGROUND: We have developed a GWAS analysis method called DEPTH (DEPendency of association on the number of Top Hits) to identify genomic regions potentially associated with disease by considering overlapping groups of contiguous markers (e.g. single nucleotide polymorphisms, SNPs) across the genome. DEPTH is a machine learning algorithm for feature ranking of ultra-high dimensional datasets, built from well-established statistical tools such as bootstrapping, penalised regression and decision trees...
August 18, 2016: Cancer Epidemiology, Biomarkers & Prevention
Jad El-Hoss, Duohui Jing, Kathryn Evans, Cara Toscan, Jinhan Xie, Hyunjoo Lee, Renea A Taylor, Mitchell G Lawrence, Gail P Risbridger, Karen L MacKenzie, Rosemary Sutton, Richard B Lock
Patient derived xenografts (PDXs) have become a vital, frequently used, component of anti-cancer drug development. PDXs can be serially passaged in vivo for years, and shared across laboratories. As a consequence, the potential for mis-identification and cross-contamination is possible, yet authentication of PDXs appears limited. We present a PDX Authentication System (PAS), by combining a commercially available OpenArray assay of single nucleotide polymorphisms (SNPs) with in-house R studio programs, to validate PDXs established in individual mice from acute lymphoblastic leukemia biopsies...
August 9, 2016: Oncotarget
Haiyang Guo, Musaddeque Ahmed, Fan Zhang, Cindy Q Yao, SiDe Li, Yi Liang, Junjie Hua, Fraser Soares, Yifei Sun, Jens Langstein, Yuchen Li, Christine Poon, Swneke D Bailey, Kinjal Desai, Teng Fei, Qiyuan Li, Dorota H Sendorek, Michael Fraser, John R Prensner, Trevor J Pugh, Mark Pomerantz, Robert G Bristow, Mathieu Lupien, Felix Y Feng, Paul C Boutros, Matthew L Freedman, Martin J Walsh, Housheng Hansen He
Long noncoding RNAs (lncRNAs) represent an attractive class of candidates to mediate cancer risk. Through integrative analysis of the lncRNA transcriptome with genomic data and SNP data from prostate cancer genome-wide association studies (GWAS), we identified 45 candidate lncRNAs associated with risk to prostate cancer. We further evaluated the mechanism underlying the top hit, PCAT1, and found that a risk-associated variant at rs7463708 increases binding of ONECUT2, a novel androgen receptor (AR)-interacting transcription factor, at a distal enhancer that loops to the PCAT1 promoter, resulting in upregulation of PCAT1 upon prolonged androgen treatment...
October 2016: Nature Genetics
Sarah L Kerns, Leila Dorling, Laura Fachal, Søren Bentzen, Paul D P Pharoah, Daniel R Barnes, Antonio Gómez-Caamaño, Ana M Carballo, David P Dearnaley, Paula Peleteiro, Sarah L Gulliford, Emma Hall, Kyriaki Michailidou, Ángel Carracedo, Michael Sia, Richard Stock, Nelson N Stone, Matthew R Sydes, Jonathan P Tyrer, Shahana Ahmed, Matthew Parliament, Harry Ostrer, Barry S Rosenstein, Ana Vega, Neil G Burnet, Alison M Dunning, Gillian C Barnett, Catharine M L West
Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. Development of a test predicting risk of toxicity could benefit many cancer patients. We aimed to meta-analyze individual level data from four genome-wide association studies from prostate cancer radiotherapy cohorts including 1564 men to identify genetic markers of toxicity. Prospectively assessed two-year toxicity endpoints (urinary frequency, decreased urine stream, rectal bleeding, overall toxicity) and single nucleotide polymorphism (SNP) associations were tested using multivariable regression, adjusting for clinical and patient-related risk factors...
August 2016: EBioMedicine
Z Nikolić, D Savić Pavićević, N Vučić, S Cerović, V Vukotić, G Brajušković
PURPOSE: The purpose of this study is to evaluate the potential association between genetic variants in genes encoding the components of RNA-induced silencing complex and prostate cancer (PCa) risk. Genetic variants chosen for this study are rs3742330 in DICER1, rs4961280 in AGO2, rs784567 in TARBP2, rs7813 in GEMIN4 and rs197414 in GEMIN3. METHODS: The study involved 355 PCa patients, 360 patients with benign prostatic hyperplasia and 318 healthy controls. For individuals diagnosed with PCa, clinicopathological characteristics including serum prostate-specific antigen level at diagnosis, Gleason score (GS) and clinical stage were determined...
August 6, 2016: World Journal of Urology
Nishi Karunasinghe, Yifei Zhu, Dug Yeo Han, Katja Lange, Shuotun Zhu, Alice Wang, Stephanie Ellett, Jonathan Masters, Megan Goudie, Justin Keogh, Benji Benjamin, Michael Holmes, Lynnette R Ferguson
BACKGROUND: Androgen deprivation therapy (ADT) is an effective palliation treatment in men with advanced prostate cancer (PC). However, ADT has well documented side effects that could alter the patient's health-related quality of life (HRQoL). The current study aims to test whether a genetic stratification could provide better knowledge for optimising ADT options to minimize HRQoL effects. METHODS: A cohort of 206 PC survivors (75 treated with and 131 without ADT) was recruited with written consent to collect patient characteristics, clinical data and HRQoL data related to PC management...
2016: BMC Urology
Sara Karami, Younghun Han, Mala Pande, Iona Cheng, James Rudd, Brandon L Pierce, Ellen L Nutter, Fredrick R Schumacher, Zsofia Kote-Jarai, Sara Lindstrom, John S Witte, Shenying Fang, Jiali Han, Peter Kraft, David J Hunter, Fengju Song, Rayjean J Hung, James McKay, Stephen B Gruber, Stephen J Chanock, Angela Risch, Hongbing Shen, Christopher A Haiman, Lisa Boardman, Cornelia M Ulrich, Graham Casey, Ulrike Peters, Ali Amin Al Olama, Andrew Berchuck, Sonja I Berndt, Stephane Bezieau, Paul Brennan, Hermann Brenner, Louise Brinton, Neil Caporaso, Andrew T Chan, Jenny Chang-Claude, David C Christiani, Julie M Cunningham, Douglas Easton, Rosalind A Eeles, Timothy Eisen, Manish Gala, Steven J Gallinger, Simon A Gayther, Ellen L Goode, Henrik Grönberg, Brian E Henderson, Richard Houlston, Amit D Joshi, Sébastien Küry, Mari T Landi, Loic Le Marchand, Kenneth Muir, Polly A Newcomb, Jenny Permuth-Wey, Paul Pharoah, Catherine Phelan, John D Potter, Susan J Ramus, Harvey Risch, Joellen Schildkraut, Martha L Slattery, Honglin Song, Nicolas Wentzensen, Emily White, Fredrik Wiklund, Brent W Zanke, Thomas A Sellers, Wei Zheng, Nilanjan Chatterjee, Christopher I Amos, Jennifer A Doherty
Telomeres cap chromosome ends, protecting them from degradation, double-strand breaks, and end-to-end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded by TERC. Loci in the TERT and adjoining CLPTM1L region are associated with risk of multiple cancers. We therefore investigated associations between variants in 22 telomere structure and maintenance gene regions and colorectal, breast, prostate, ovarian, and lung cancer risk. We performed subset-based meta-analyses of 204,993 directly-measured and imputed SNPs among 61,851 cancer cases and 74,457 controls of European descent...
December 15, 2016: International Journal of Cancer. Journal International du Cancer
Christian Nicolaj Andreassen, Barry S Rosenstein, Sarah L Kerns, Harry Ostrer, Dirk De Ruysscher, Jamie A Cesaretti, Gillian C Barnett, Alison M Dunning, Leila Dorling, Catharine M L West, Neil G Burnet, Rebecca Elliott, Charlotte Coles, Emma Hall, Laura Fachal, Ana Vega, Antonio Gómez-Caamaño, Christopher J Talbot, R Paul Symonds, Kim De Ruyck, Hubert Thierens, Piet Ost, Jenny Chang-Claude, Petra Seibold, Odilia Popanda, Marie Overgaard, David Dearnaley, Matthew R Sydes, David Azria, Christine Anne Koch, Matthew Parliament, Michael Blackshaw, Michael Sia, Maria J Fuentes-Raspall, Teresa Ramon Y Cajal, Agustin Barnadas, Danny Vesprini, Sara Gutiérrez-Enríquez, Meritxell Mollà, Orland Díez, John R Yarnold, Jens Overgaard, Søren M Bentzen, Jan Alsner
PURPOSE: Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-powered study, an individual patient data meta-analysis was carried out by the International Radiogenomics Consortium. MATERIALS AND METHODS: The analysis included 5456 patients from 17 different cohorts. 2759 patients were given radiotherapy for breast cancer and 2697 for prostate cancer...
July 18, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
M Liu, N Miao, Y Zhu, C Y Gu, X L Shi, W L Cui, W Zhang, Q X Li
OBJECTIVE: To study the associations between genetic variations of Vav3 gene and prostate cancer susceptibility. METHODS: Data were collected in a hospital-based and case-control study of 1 015 prostate cancer cases and 1 068 cancer-free controls collecting from a period of time between 2008 and 2012. Based on the online database, NCBI dbSNP (http: // and SNPinfo (http: // Functional single nucleotide polymorphisms (SNPs) of Vav3 were screened and genotyped, and assessed their associations with risk of prostate cancer by using logistic regression analysis...
July 8, 2016: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
Ben Y Zhang, Shaun M Riska, Douglas W Mahoney, Brian A Costello, Rhea Kohli, J F Quevedo, James R Cerhan, Manish Kohli
OBJECTIVES: To evaluate the prognostic significance of germline variation in candidate genes in patients with castration-resistant prostate cancer (CRPC). METHODS: Germline DNA was extracted from peripheral blood mononuclear cells of CRPC patients enrolled in a clinically annotated registry. Fourteen candidate genes implicated in either initiation or progression of prostate cancer were tagged using single nucleotide polymorphisms (SNPs) from HapMap with minor allele frequency of >5%...
July 13, 2016: BJU International
Moritz Binder, Ben Y Zhang, David W Hillman, Rhea Kohli, Tanvi Kohli, Adam Lee, Manish Kohli
Treatment with abiraterone acetate and prednisone (AA/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. We evaluated the genetic variation in CYP17A1 as predictive of response to AA/P. A prospective collection of germline DNA prior to AA/P initiation and follow-up of a mCRPC cohort was performed. Five common single-nucleotide polymorphisms (SNPs) in CYP17A1 identified using a haplotype-based tagging algorithm were genotyped. Clinical outcomes included biochemical response and time to biochemical progression on AA/P...
2016: International Journal of Molecular Sciences
Jean-Nicolas Cornu, Etienne Audet-Walsh, Sarah Drouin, Pierre Bigot, Antoine Valeri, Georges Fournier, Abdel-Rahmène Azzouzi, Morgan Roupret, Luc Cormier, Stephen Chanock, Chantal Guillemette, Olivier Cussenot, Eric Lévesque, Géraldine Cancel-Tassin
OBJECTIVES: A few preliminary studies have suggested a link between some genetics variants and benign prostatic hyperplasia (BPH). Our goal was to study the link between a set of single nucleotide polymorphisms (SNPs) implicated in the steroid pathway and accurate measurement of prostate volume in a cohort of men who underwent radical prostatectomy. METHODS: Clinical and pathological data including prostate weight were obtained from 611 Caucasian patients with small volume, localized prostate cancer treated by radical prostatectomy...
June 8, 2016: World Journal of Urology
Y S Kim, Y Kim, J W Choi, H E Oh, J H Lee
This study explored candidate causal single nucleotide polymorphisms (SNPs) to clarify the biological mechanism of prostate cancer (PCa). Identify candidate Causal SNPs and Pathways (ICSNPathway) analysis was applied using a PCa genome-wide association study (GWAS) dataset that included 473,736 SNPs in 1151 cases of PCa and 1156 controls of European ancestry. Five candidate causal SNPs, three candidate causal genes, and two candidate causal pathways were identified using integrating linkage disequilibrium analysis, functional SNP annotation, and pathway-based analysis...
2016: Neoplasma
Craig C Teerlink, Daniel Leongamornlert, Tokhir Dadaev, Alun Thomas, James Farnham, Robert A Stephenson, Shaun Riska, Shannon K McDonnell, Daniel J Schaid, William J Catalona, S Lilly Zheng, Kathleen A Cooney, Anna M Ray, Kimberly A Zuhlke, Ethan M Lange, Graham G Giles, Melissa C Southey, Liesel M Fitzgerald, Antje Rinckleb, Manuel Luedeke, Christiane Maier, Janet L Stanford, Elaine A Ostrander, Elina M Kaikkonen, Csilla Sipeky, Teuvo Tammela, Johanna Schleutker, Kathleen E Wiley, Sarah D Isaacs, Patrick C Walsh, William B Isaacs, Jianfeng Xu, Geraldine Cancel-Tassin, Olivier Cussenot, Diptasri Mandal, Cecelia Laurie, Cathy Laurie, Stephen N Thibodeau, Rosalind A Eeles, Zsofia Kote-Jarai, Lisa Cannon-Albright
Previous genome-wide association studies (GWAS) of prostate cancer risk focused on cases unselected for family history and have reported over 100 significant associations. The International Consortium for Prostate Cancer Genetics (ICPCG) has now performed a GWAS of 2511 (unrelated) familial prostate cancer cases and 1382 unaffected controls from 12 member sites. All samples were genotyped on the Illumina 5M+exome single nucleotide polymorphism (SNP) platform. The GWAS identified a significant evidence for association for SNPs in six regions previously associated with prostate cancer in population-based cohorts, including 3q26...
August 2016: Human Genetics
Elena Castro, Christos Mikropoulos, Elizabeth K Bancroft, Tokhir Dadaev, Chee Goh, Natalie Taylor, Edward Saunders, Nigel Borley, Diana Keating, Elizabeth C Page, Sibel Saya, Stephen Hazell, Naomi Livni, Nandita deSouza, David Neal, Freddie C Hamdy, Pardeep Kumar, Antonis C Antoniou, Zsofia Kote-Jarai, Rosalind A Eeles
BACKGROUND: A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of PrCa to investigate the probability of detecting PrCa at prostate biopsy (PB)...
June 2016: Oncologist
Neeraj Agarwal, Anitha B Alex, James M Farnham, Shiven Patel, David Gill, Tyler H Buckley, Robert A Stephenson, Lisa Cannon-Albright
PURPOSE: Germline variations in genes involved in androgen biosynthesis and metabolic pathways may predict the response to abiraterone acetate in men with metastatic, castration refractory prostate cancer. The variations may serve as prognostic and predictive biomarkers to allow for more individualized therapy. MATERIALS AND METHODS: We evaluated 832 single nucleotide polymorphisms from the OmniExpress genotyping platform (Illumina®) in the boundaries of 61 candidate genes reported to be involved in the androgen metabolic pathway...
October 2016: Journal of Urology
Daniel L Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William K Kelly, Jai N Patel, Susan Halabi, Yoichi Furukawa, Heather E Wheeler, Alexander Sibley, Cameron Lassiter, Lois S Weisman, Dorothy Watson, Stefanie D Krens, Flora Mulkey, Cynthia L Renn, Eric J Small, Philip G Febbo, Ivo Shterev, Deanna Kroetz, Paula N Friedman, John F Mahoney, Michael A Carducci, Michael J Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G Dorsey, M Eileen Dolan, Michael J Morris, Mark J Ratain, Howard L McLeod
PURPOSE: Discovery of single nucleotide polymorphisms (SNPs) that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with docetaxel-induced neuropathy and mechanistically validate these associations in preclinical models of drug-induced neuropathy. EXPERIMENTAL DESIGN: A genome-wide association study was conducted in metastatic castrate-resistant prostate cancer patients treated with docetaxel, prednisone and randomized to bevacizumab or placebo on CALGB 90401...
May 3, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"